Cardioproteomics : Insights on Cardiovascular Diseases
© 2024. The Author(s), under exclusive license to Springer Nature Switzerland AG..
Cardiovascular diseases (CVDs) remain a global health challenge and are the leading cause of deaths worldwide. Proteomics has emerged as a valuable tool for unraveling the complex molecular mechanisms underlying CVDs, offering insights into biomarker discovery, drug targets, and personalized medicine. This review explores key breakthroughs in proteomic applications related to CVDs, mainly coronary artery disease (CAD), ischemic heart diseases such as myocardial infarction (MI), and cardiomyopathies. Notable findings include potential biomarkers, therapeutic targets, and insights into disease pathogenesis. The review highlights the importance of proteomics in advancing our understanding of CVDs and shaping future therapeutic approaches.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:1443 |
|---|---|
| Enthalten in: |
Advances in experimental medicine and biology - 1443(2024) vom: 26., Seite 159-171 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Raíssa-Oliveira, Brenda [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Atherosclerosis |
|---|
| Anmerkungen: |
Date Completed 28.02.2024 Date Revised 28.02.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1007/978-3-031-50624-6_8 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368993833 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368993833 | ||
| 003 | DE-627 | ||
| 005 | 20240229171226.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240229s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/978-3-031-50624-6_8 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1310.xml |
| 035 | |a (DE-627)NLM368993833 | ||
| 035 | |a (NLM)38409420 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Raíssa-Oliveira, Brenda |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cardioproteomics |b Insights on Cardiovascular Diseases |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.02.2024 | ||
| 500 | |a Date Revised 28.02.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s), under exclusive license to Springer Nature Switzerland AG. | ||
| 520 | |a Cardiovascular diseases (CVDs) remain a global health challenge and are the leading cause of deaths worldwide. Proteomics has emerged as a valuable tool for unraveling the complex molecular mechanisms underlying CVDs, offering insights into biomarker discovery, drug targets, and personalized medicine. This review explores key breakthroughs in proteomic applications related to CVDs, mainly coronary artery disease (CAD), ischemic heart diseases such as myocardial infarction (MI), and cardiomyopathies. Notable findings include potential biomarkers, therapeutic targets, and insights into disease pathogenesis. The review highlights the importance of proteomics in advancing our understanding of CVDs and shaping future therapeutic approaches | ||
| 650 | 4 | |a Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Atherosclerosis | |
| 650 | 4 | |a Cardiomyopathy | |
| 650 | 4 | |a Cardioproteomics | |
| 650 | 4 | |a Cardiovascular diseases | |
| 650 | 4 | |a Ischemic heart diseases | |
| 700 | 1 | |a Lara-Ribeiro, Ana Carolina |e verfasserin |4 aut | |
| 700 | 1 | |a Rezende-Ribeiro, Júlia |e verfasserin |4 aut | |
| 700 | 1 | |a Bahia, Ana Beatriz Queiroz |e verfasserin |4 aut | |
| 700 | 1 | |a Verano-Braga, Thiago |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Advances in experimental medicine and biology |d 1971 |g 1443(2024) vom: 26., Seite 159-171 |w (DE-627)NLM000012157 |x 0065-2598 |7 nnns |
| 773 | 1 | 8 | |g volume:1443 |g year:2024 |g day:26 |g pages:159-171 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/978-3-031-50624-6_8 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 1443 |j 2024 |b 26 |h 159-171 | ||